In the multicenter, real-world FLOWER Study in Italy, 44 of 126 EGFR mutant advanced NSCLC patients had disease progression and 20.1% of them had oligoprogression and 54.5% had systemic progression (Lorenzi et al., 2022). This evidence concerns the gene EGFR and non-small cell lung carcinoma.